Quarterly ResultMay 12, 2026, 04:48 PM
Impact BioMedical Q1 Net Loss Widens to $2.28M; Revenue $7K
AI Summary
Impact BioMedical Inc. reported a net loss of $2.28 million for Q1 2026, a significant increase from $1.28 million in Q1 2025. Revenue for the quarter was $7,000, up from zero in the prior year. The company continues to face a going concern risk due to sustained operating losses and negative cash flows, despite a slight improvement in cash from operating activities.
Key Highlights
- Net loss for Q1 2026 widened to $(2,284,000) from $(1,278,000) in Q1 2025.
- Total revenue for Q1 2026 was $7,000, compared to $0 in Q1 2025.
- Basic and diluted loss per share was $(0.02) in Q1 2026, down from $(0.11) in Q1 2025 due to increased shares.
- Cash and cash equivalents increased to $20,000 as of March 31, 2026, from $3,000 at December 31, 2025.
- Net cash used in operating activities improved to $(464,000) in Q1 2026 from $(682,000) in Q1 2025.
- Due to related party increased to $1,103,000 as of March 31, 2026, from $621,000 at December 31, 2025.
- Stock-based compensation significantly increased to $1,440,000 in Q1 2026 from $2,000 in Q1 2025.
- The company faces substantial doubt about its ability to continue as a going concern.